Multiple system atrophy (MSA) is a neurodegenerative disorder that occurs sporadically and causes parkin sonism, cerebellar, autonomic, urinary, and pyramidal dysfunction in many combinations. Progressive Ldopa-unresponsive parkinsonism due to underlying striatonigral degeneration dominates the clinical syn drome in the majority of cases (MSA-P subtype). MSA-P is characterized pathologically by degenerative changes in somatotopically related areas of the substantia nigra pars compacta and of the putamen. Further more, oligodendroglial cytoplasmic inclusions (GCIs) are observed throughout the cortico-striato-pallidocortical loops and may contribute to the basal ganglia dysfunction. Neurotransplantation strategies are of potential interest in this disease, which causes marked and early disability and dramatically reduces life expectancy. A number of experimental MSA-P models have been employed to evaluate neurotransplantation approaches. Sequential nigral and striatal lesions using 6-hydroxydopamine and quinolinic acid (double toxin-double lesion approach) indicate that apomorphine-induced contralateral rotation is abolished by a secondary striatal lesion. Intrastriatal injection of mitochondrial respiratory chain toxins produces secondary excitotoxic striatal lesions combined with retrograde nigral degeneration and therefore provides an alternative single toxin-double lesion approach. Neurotransplantation in MSA-P animal models has been used to im prove functional deficits by replacing lost nigral and/or striatal circuitry (neuroregenerative approach). The available data indicate that embryonic mesencephalic grafts alone or combined with striatal grafts partially reverse drug-induced rotation asymmetries without improving deficits of complex motor function. The poten tial neuroprotective efficacy of embryonic striatal grafts against striatal excitotoxicity is presently under investigation in the double toxin-double lesion MSA-P rat model. Anecdotal clinical evidence in one MSA-P patient misdiagnosed as Parkinson's disease indicates that embryonic mesencephalic grafts produce incom plete clinical benefit. Striatal co-grafts may increase functional improvement. Further experimental studies are required prior to the clinical application of embryonic neurotransplantation in MSA-P. Future research strategies should explore the effect of neurotransplantation in partial MSA-P rat models with less severe nigral and striatal degeneration, the feasibility of a primate model closely mimicking the human disease, and the replication of oligodendroglial dysfunction.
INTRODUCTION
Multiple system atrophy (MSA) is a term introduced by Graham and Oppenheimer in 1969 to describe a spo radic neurodegenerative disorder causing parkinsonism, cerebellar ataxia, autonomic failure, urogenital dysfunc tion, and pyramidal signs in any combination (32) . Un fortunately, the complex nosology of MSA has produced much confusion in clinical practice and scientific re search. Since the turn of the century MSA patients with a late-onset predominant cerebellar disorder had been labeled as "sporadic olivopontocerebellar atrophy" (sOPCA) (5, 18) . Striatonigral degeneration (SND) be came established as the underlying neuropathological substrate of a form of malignant parkinsonism in the early 1960s (1) . However, James Parkinson himself may have described the rapid progression of MSA-parkinsonism in one of his patients (62) . Finally, early and severe autonomic failure followed by extrapyramidal and/or cerebellar dysfunction had been established as core fea tures of the "Shy Drager Syndrome" (SDS) (73) . The discovery in 1989 of glial cytoplasmic inclusions (GCIs) in the brains of patients with MSA provided a neuro pathological marker for the disorder and confirmed that SND, sOPCA, and SDS constitute a single clinicopathological entity with parkinsonian, cerebellar, and auto-nomic presentations (51) . A recent consensus conference proposed a simplified terminology designating patients as having MSA-P instead of MSA-SND if parkinsonian features predominate or MSA-C instead of MSA-OPCA if cerebellar features predominate (24) . The term SDS was rejected due to past misuse and the presence of some degree of autonomic failure in all MSA patients (24) . Parkinsonism represents the most frequent motor deficit of MSA. In a large meta-analysis of 203 patho logically proven MSA cases reported in the literature up to 1995, parkinsonian features were present in 176 (87%) cases and cerebellar ataxia in 110 (54%) cases (85) .
MSA-P may be the most common cause of parkin sonism after Parkinson's disease (PD) (61) . L-dopa re sponse failure is frequent in MSA-P but rare in PD.
Compared to PD, disease progression is more rapid and life expectancy shorter in MSA-P (81) . Neurotransplan tation in MSA-P may provide a novel therapeutic strat egy with symptomatic and/or neuroprotective efficacy.
In this article we initially review the pathophysiological basis of parkinsonism in MSA-P in order to define the requirements for neurorestorative intervention. This is followed by a discussion of existing and future animal models of MSA-P. We then consider the results of neu ral transplantation in experimental and anecdotal clinical reports. Finally, we propose some new directions for further experimental research.
PATHOPHYSIOLOGY OF PARKINSONISM IN MSA-P
In MSA-P the degenerative process affects nigrostria tal dopaminergic transmission at both pre-and postsyn aptic sites (17, 22, 39) . The loss of dopaminergic neurons in MSA-P is comparable to that found in PD, but, in addition, moderate to severe putaminal degeneration is present in most (>90%) cases (79) . Degeneration of pig mented dopaminergic neurons begins and predominates in the caudal and lateral substantia nigra pars compacta.
As a consequence, the loss of nigral dopaminergic termi nals predominates in the caudal and dorsolateral puta men (22) . The putaminal degeneration begins in the pos terior and dorsolateral aspects and then spreads rostrally and ventrally (17, 22, 39) , a subregional distribution simi lar to that found in Huntington's disease (HD) (80) .
However, contrary to HD, the caudate nucleus is less severely affected in MSA (80) . These areas of preferen tial degeneration in substantia nigra and striatum are re ciprocally connected (13, 22, 27, 38, 39) . This observation raises the possibility of a transsynaptic degenerative pro cess; however, the severity of nigral and striatal lesions fails to correlate in human postmortem studies (22, 39, 79) . In MSA-P "small" striatal cells corresponding to GABAergic medium-sized spiny neurons (MSNs) de generate to a large extent (17, 22) . Such loss of GABAer gic projection neurons seems to predominate in the ma trix compartment as demonstrated by calcineurin immunohistochemistry (27) . In 75% of definite MSA cases reported in the literature, "small" cells were more affected than "large" cells, the latter corresponding to cholinergic interneurons (79) . However, large interneur ons and small cells were equally depleted in a single morphometric study of 10 MSA cases (22) . Postmortem immunohistochemical and receptor binding studies sug gest that both striatal outflow pathways are affected in MSA-P: enkephalinergic (ENK) dopamine D 2 receptorbearing striatal neurons projecting to external globus pallidus (GPe) (indirect pathway) and striatal neurons coexpressing substance P (SP) and dopamine D, recep tors that project to internal globus pallidus (GPi) and substantia nigra pars reticulata (direct pathway) (14, (27) (28) (29) (30) 36, 60) .
There is a single autoradiographic postmortem study suggesting that disease process may initially affect the indirect striatopallidal pathway and subsequently, with increasing disease duration, the direct striatopallidal pathway (14) . Pallidal gliosis affects the external seg ment (GPe) in >80% of cases and the internal segment In MSA glial and neu ronal cytoplasmic inclusions are found along the cortico-striato-cortical motor loop, principally in the striatum, pallidum, and supplementary motor cortex. The density of inclusions is signified as follows: *** high, ** moderate, * low, or absent (53) . In MSA, the degree of GPi hyperactivity may depend on the combination of lesions in the striatrum and GPe. CTX: motor cortex; ST: striatum; GPi/SNr: internal globus pallidus/ substantia nigra pars reticulata; GPe: external globus pallidus; SN: substantia nigra pars compacta; ENK: enkephalin; SP: substance P; DA: dopamine. Amphetamine-and apomorphine-induced rotation rates were consistent with a >90% loss of striatal dopamine (34, 67) and a >90% loss of tyrosine hydroxylase (TH)-positive cells in the substantia nigra pars compacta (8) .
Following the subsequent striatal lesion, amphetamineinduced ipsilateral rotation persisted, but apomorphineinduced contralateral rotation was significantly reduced.
Neuropathological evaluation of the striatal lesion indi cated marked loss of dopamine and cyclic adenosine 3':
5'-monophosphate-regulated phosphoprotein 32 (DARPP-32) expression in the dorsolateral striatum accounting for the reduction in contralateral apomorphine-induced rotation (Fig. 2) .
In a separate experiment we used autoradiography to investigate changes of striatal dopamine D| and D 2 re ceptor binding (57) and loss of dopamine reuptake sites (58) in the double lesion MSA-P rat model. The initial unilateral 6-OHDA lesion resulted in 95% loss of striatal dopamine reuptake sites consistent with the observed amphetamine-and apomorphine-induced circling. Sub sequent QA injections into dorsolateral striatum again produced variable lesions with a remaining average sur face area of about 40% compared to the intact side. The observed reduction of apomorphine rotation failed to correlate with residual striatal surface areas and specific dopamine D, and D 2 receptor binding on the lesioned relative to intact side. In contrast, Barker and Dunnett (2) reported significant correlations between extent of striatal atrophy or reduction in number of striatal parval bumin neurons and change in apomorphine-induced ro tation following stereotaxic injection of the striatal toxin ibotenic acid in 6-OHDA prelesioned rats. QA-induced striatal damage may be more diffuse, and hence more variable, compared to that induced by ibotenic acid (89) . Interindividual variations of striatal degeneration occa sionally extending to ventral striatal pathways known to augment circling behavior (59) may account for the lack of correlations in our 6-OHDA/QA double lesion model. Furthermore, all our double-lesioned animals subse quently received embryonic neuronal or sham grafts, which may have modified ongoing striatal atrophy (see below), thereby adding complexity to the analysis of double lesion effects on rotation behavior.
Disturbances of complex motor function in the dou ble lesion MSA-P model were characterized by our group using the paw-reaching or staircase test (47, 66) . Confirming previous reports (47,50) we observed pro found contralateral paw-reaching deficits in unilaterally 6-OHDA-lesioned rats. This marked impairment of con tralateral motor function failed to change significantly following QA-induced striatal degeneration (66) (Fig.  3) . Whereas nigral lesions were consistently marked, with >95% loss of dopaminergic neurons in the substan tia nigra pars compacta, striatal lesions appeared more variable. Either observation may partly account for the lack of correlations between paw-reaching deficits and extent of nigral and striatal lesions. Furthermore, func tional and structural heterogeneity of the striatum may have also contributed (21) .
Although the present data fail to correlate loss of apo morphine-induced rotation with the extent of the striatal lesion, apomorphine may still be helpful to monitor stri atal dysfunction in the sequential double lesion MSA-P rodent model. Dose-response studies using different survival times and a range of concentrations of nigral and striatal toxins are required to further explore the re lationship between rotation behavior and structural le sions. Selective subregional dopaminergic denervation
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ipsilateral paw contralateral paw 6-OHDA-*-QA 6-OHDA-*-QA Figure 3 . Average paw-reaching ability evaluated over 13 consecutive days (only last 5 days were analyzed) in rats re ceiving sequential unilateral nigral and striatal lesions using 6-hydroxydopamine (6-OHDA) and quinolinic acid (QA). The contralateral paw displays marked impairment following the initial 6-OHDA lesion. The subsequent striatal QA lesion fails to exacerbate the contralateral paw-reaching impairment. There are a number of intriguing analogies between behavioral deficits observed in double-lesioned animals and clinical features of MSA-P that are summarized in the Table 1 .
The Single Toxin-Double Lesion Approach
A number of mitochondrial respiratory chain inhibi In principle, nigral and striatal neurotoxins such as MPTP and 3-NP may be administered sequentially by systemic injections. To our knowledge, this approach has not hitherto been used, although it avoids local non specific damage induced by stereotaxic surgery. How ever, bilateral lesions are inevitable and careful dose ti tration will be required to avoid excess mortality.
MSA-P AND NEUROTRANSPLANTATION
Transplantation of embryonic neural tissue has been firmly established in PD and HD animal models (49, 55) .
Clinical trials have demonstrated long-term benefits in PD (33, 86) and have been launched in HD.
Experimental Studies
Thus far, there has been only one study that has re ported on the effects of embryonic transplants in rodents with experimental lesions of both substantia nigra and (57, 83) striatum. This showed partial functional benefits induced by embryonic grafts (83, 84) . Prior to transplantation these animals had received a sequential unilateral lesion of substantia nigra pars compacta and striatum as out lined above. The lesioned striatum was implanted with embryonic neuronal allografts consisting of cell suspen sions derived from both El3 striatal primordium and ventral mesencephalon, or either alone. Rats receiving a mixed or pure mesencephalic graft showed a significant reduction of amphetamine-induced rotation 10 weeks following transplantation. This was not observed in ani mals receiving striatal grafts alone. Apomorphine-in duced contraversive rotation was significantly increased 10 weeks following striatal, but not mesencephalic, mixed or sham transplantation. The characteristic druginduced rotational response associated with the sequen tial nigral and striatal lesion was therefore partly re versed by pure mesencephalic and mixed mesencephalic striatal grafts. TH and DARPP-32 immunocytochemis try showed mesencephalic and striatal graft survival in most animals (Fig. 4) . There was no significant differ ence in the number of surviving dopaminergic neurons in rats receiving pure mesencephalic versus mixed grafts. The additional striatal graft component therefore failed to enhance the behavioral recovery and survival of grafted dopaminergic neurons in our double lesion MSA-P model (84) . This is in contrast to the reported amelioration of rotational behavior and enhanced matu ration of embryonic dopaminergic neurons co-grafted with cell suspensions derived from striatal primordium in PD rat models (11, 15, 16, 91) . A subsequent autoradio graphic characterization of dopamine reuptake sites us ing tritiated mazindol confirmed surviving mesence phalic or mixed grafts in most animals, with variable numbers of "hot spots" (distinct areas of high receptor binding) (58) . However, there was no evidence of rein nervation of the severely lesioned adult striatum. There fore, a dopamine pump-like effect comparable to adrenal medullary grafts (4) is likely to account for the observed reduction of amphetamine-induced rotation in animals receiving ventral mesencephalic grafts. Dopamine re ceptor autoradiography using SCH23390 (D, receptor li gand) and spiperone (D 2 receptor ligand) revealed a 60-70% loss of striatal surface area largely affecting the dorsolateral circumference across all sham and embry onic graft groups. Hot spots were identified in most ani mals receiving striatal or mixed grafts. There was no significant correlation between change of posttransplan tation apomorphine rotation rates and dopamine D| or D 2 receptor binding within the graft or lesioned striatum relative to the intact side.
Striatal protection against QA excitotoxicity using embryonic striatal grafts 4 weeks prior to ipsilateral QA injection was reported by Levivier et al. (44) . These in- vestigators proposed that striatal grafts may offer a neu roprotective strategy in the treatment of HD patients. Encouraged by these findings we investigated the neuro protective potential of E14 striatal grafts implanted 4 weeks prior to QA injection in 6-OHDA-prelesioned rats. Double-lesioned control animals received sham injections instead of embryonic grafts. Apomorphine-in duced rotation behavior was assessed following 6-OHDA administration, 2 and 4 weeks after striatal graft ing and 2 and 4 weeks after QA lesioning. Behavioral data indicate that the striatal grafts failed to confer pro tection against striatal excitotoxicity as the marked loss of apomorphine-induced contralateral rotation was simi lar in both situations. Autoradiography and in situ hy bridization are presently being performed to elucidate the underlying changes of dopamine receptors and reup take sites.
Using the intrastriatal 3-NP rat model reported by Nakao and colleagues (48) we assessed the restorative effects of pure mesencephalic, pure striatal, and mesen- 
CONCLUSIONS AND FUTURE DIRECTIONS
There is a large body of evidence indicating that the Finally, chronic primate MSA-P models will be re quired to closer mimic the human disease that is domi nated by progressive L-dopa-resistant parkinsonism.
Candidate neurotoxins in a primate MSA-P model in clude MPTP, which produces a highly selective loss of dopaminergic neurons of the substantia nigra pars com pacta through acute/subacute or chronic systemic admin istration (7), and 3-NP, which produces striatal excito toxic lesions that exhibit HD-like pathology (10) . These toxins may be administered sequentially to obtain a combined nigral and striatal degeneration resulting in Ldopa-resistant parkinsonism. However, prior to develop ing a primate MSA-P model concerns of increased tox icity and mortality resulting from sequential MPTP and 3-NP administration should be addressed in mice, which are sensitive to both toxins (6, 31) .
In the meantime, further progress in the understand ing of the natural history of MSA-P will help select ap propriate clinical and imaging progression indices as well as define the optimal time window for interven tional therapies. A European MSA Study Group is pres ently being established to address these issues.
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